524-36-7 Usage
Description
Pyridoxamine dihydrochloride is a salt of pyridoxamine, which is a member of the vitamin B6 family of compounds. It is naturally found in animal-based food products and plays a crucial role in human health, as its deficiency can lead to sideroblastic anemia, weakness, insomnia, and neurological disorders. Pyridoxamine dihydrochloride has been reported to be effective against diabetic nephropathy and is also used in organic synthesis.
Uses
Used in Pharmaceutical Applications:
Pyridoxamine dihydrochloride is used as a therapeutic agent for the treatment of diabetic nephropathy. It blocks pathogenic oxidative pathways in the progression of the disease and has been shown to slow down the progression of diabetic kidney disease (DKD) in patients with relatively preserved kidney function (i.e., baseline SCr 1.3 to 1.9 mg/dL).
Used in Organic Synthesis:
Pyridoxamine dihydrochloride (CAS# 524-36-7) is a compound that is useful in organic synthesis, contributing to the development of various chemical compounds and products.
Used in Mammalian Cell Culture:
Pyridoxamine dihydrochloride is used as an alternative to pyridoxine or pyridoxal in mammalian cell culture. Vitamin B6 is a required component of cell culture media, and historically, media have been supplemented with the aldehyde form, pyridoxal. However, pyridoxal is unstable in liquid media, making pyridoxamine a preferred supplement when cells can utilize either pyridoxine and/or pyridoxamine. A number of classical media are now offered with a choice between pyridoxal and pyridoxine as the vitamin B6 source.
Chemical Properties:
Pyridoxamine dihydrochloride is a white crystalline powder that can be obtained by combining pyridoxamine with two molar equivalents of hydrochloric acid.
Preparation
The invention relates to a preparation method of pyridoxamine dihydrochloride, belonging to the technical field of the preparation of water soluble vitamins. The preparation method comprises the following steps: preparing pyridoxal oxime: taking pyridoxine hydrochloride as initial raw material and water as a reaction medium, adding activated manganese dioxide and concentrated sulfuric acid to generate pyridoxal by the reaction, and then reacting with anhydrous sodium acetate and hydroxylamine hydrochloride to obtain pyridoxal oxime; preparing pyridoxamine dihydrochloride: firstly enabling pyridoxal oxime to react with acetic acid and zinc to obtain acetic acid solution containing pyridoxamine, then decompressing the solution and reclaiming the acetic acid to obtain slurry concentrate, decompressing and reclaiming the acetic acid again to obtain pyridoxamine water solution, regulating the pH value to be alkaline so as to separate pyridoxamine out, adding water and hydrochloric acid after vacuum filteration, decoloring and filtering to obtain filtrate, decompressing and concentrating the filtrate until white solids are separated out, adding solvent and stirring, and finally crystallizing at the lower temperature, filtering and drying to obtain the pyridoxamine dihydrochloride. The invention has the advantages that the prepared pyridoxamine dihydrochloride has high total mol yield and purity, and the preparation method is reduced.https://patents.google.com/patent/CN101628892A/en
Purification Methods
The amine salt is crystallised from hot MeOH. The free base crystallises from EtOH with m 193-193.5o [Harris et al. J Biol Chem 154 315 1944, J Am Chem Soc 66 2088 1944]. [Beilstein 22 IV 6064, 22/12 V 324.]
Check Digit Verification of cas no
The CAS Registry Mumber 524-36-7 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 5,2 and 4 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 524-36:
(5*5)+(4*2)+(3*4)+(2*3)+(1*6)=57
57 % 10 = 7
So 524-36-7 is a valid CAS Registry Number.
InChI:InChI=1/C8H12N2O2.2ClH/c1-5-8(12)7(2-9)6(4-11)3-10-5;;/h3,11-12H,2,4,9H2,1H3;2*1H
524-36-7Relevant articles and documents
Fabrication of ω-Transaminase@Metal-Organic Framework Biocomposites for Efficiently Synthesizing Benzylamines and Pyridylmethylamines
Chen, Lina,Ding, Yingying,Jiao, Qingcai,Liu, Junzhong,Yu, Jinhai,Zhang, Hongjuan,Zong, Weilu
, (2021/11/05)
In this study, ten ω-transaminases (ω-TAs) have been investigated to efficiently catalyze the synthesis of twenty-four functionalized benzylamines and pyridylmethylamines. We optimized the reactions, screened suitable amino donors and compared ω-transaminases activities for all aromatic aldehyde substrates. Under the optimized conditions, eighteen aromatic amines have been obtained with 60.4%–96.6% conversions and isolated only via simple extraction and recrystallization with 18.5%–81% yields on a preparative scale. Furthermore, we first immobilized the Bm-STA onto the MOFs via the physical adsorption to overcome the limitation of free enzyme and improve their industrial applications. The obtained Bm-STA/UiO-66-NH2 composites exhibited not only high enzymes loading (80.4 mg g?1) and enzyme activity recovery (95.8%), but also the better reusability, storage stability, pH stability and the tolerance to acetone and DMF.
COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS
-
Paragraph 00103; 00104, (2013/12/03)
The invention relates to the compounds of formula (I) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula (I), and methods for treating or preventing metabolic disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be also used to the treatment of diabetes, lipid peroxidation, hypertriglyceridemia, metabolic disorders, free radical generated due to reactive oxygen and carhonyl groups, ionizing radiation, advanced glycation end products, kidney disease, renal complications and kidney stone disease.
METHODS FOR THE SYNTHESIS OF PYRIDOXAMINE
-
Page/Page column 40-42, (2008/06/13)
The invention provides non-oxidative methods for the large scale manufacture of pyridoxamine (I) (4-aminomethyl-3-hydroxy-5-hydroxymethyl-2-methylpyridine): Formula (I), and salts thereof. The invention also provides intermediate compounds for the synthesis of pyridoxamine, as well as compositions and methods for the treatment and/or prevention of conditions associated with the formation of post-Amadori advanced glycation end-products.